NAD+, sermorelin and tesamorelin, explained
The three peptides in the Syra Rx anti-aging category: what each one is, what it is actually approved for, and how strong the evidence behind the marketing really is.
Syra Rx markets NAD+, sermorelin and tesamorelin under anti-aging — support for energy, focus and how you feel day to day. This page takes each in turn and separates three things that often get blurred: what the compound is, what it is approved for, and what the marketing implies.
Set expectations before you read on. The evidence base behind these three, for the purposes they are commonly marketed for, is considerably thinner than for GLP-1 medications. That does not mean they do nothing. It means confident claims about outcomes are not well supported, and you should treat them sceptically wherever you encounter them — including from a prescriber.
NAD+
What it is. Nicotinamide adenine dinucleotide, a coenzyme present in every living cell. It is central to cellular metabolism — converting nutrients into usable energy — and to processes including DNA repair. NAD+ levels decline with age, which is the entire basis for therapeutic interest in it.
What is well established. The biochemistry. NAD+ is genuinely essential, and the age-related decline is real and measured.
What is not established. Whether administering NAD+ or its precursors meaningfully changes how you feel or function. The leap from “this molecule is important and declines with age” to “supplementing it will restore energy and focus” is exactly the kind of leap that often fails when tested properly. Research is active and worth watching; it is not settled.
Marketing language to be wary of: cellular rejuvenation, reversing aging, restoring youthful energy. These describe a hypothesis, not a demonstrated outcome.
Sermorelin
What it is. A growth hormone–releasing hormone analogue. It does not supply growth hormone; it signals the pituitary gland to produce more of its own. In principle this preserves the body’s own feedback regulation, which is the argument for preferring it to direct growth hormone.
What it is established for. A clinical history in diagnostic testing of pituitary function, and in paediatric growth hormone deficiency.
What it is marketed for. Adult anti-aging, body composition, sleep quality, recovery. These uses are off-label and the supporting evidence is limited. Growth hormone pathway manipulation in healthy adults is an area where enthusiasm has consistently outrun data.
Tesamorelin
What it is. Another growth hormone–releasing factor analogue, structurally distinct from sermorelin.
What it is approved for. Tesamorelin has an FDA-approved indication, in a specific branded form, for reducing excess abdominal fat in people with HIV-associated lipodystrophy. That is a narrow, specific population.
What it is marketed for. General abdominal fat reduction and anti-aging in people without that condition. Off-label, and an approval for one population does not transfer to another.
The pattern across all three
Each has a real mechanism and, in two cases, a genuine approved indication — in a population probably unlike yours. The marketed use is broader than the evidenced use. That gap is where you should focus your questions.
The regulatory picture is unsettled
Compounded peptide products have been through repeated regulatory review through 2025 and 2026, including which peptides may lawfully be compounded at all. This has moved more than once and is still moving. Anything you read about which peptides are available, in what form, from whom, should be verified against the current position rather than trusted from a webpage.
As with GLP-1 medications: compounded peptide preparations are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness or quality.
Questions to ask before starting peptide therapy
- What specific outcome is this expected to produce, and over what timeframe?
- What evidence supports that in people like me — not in cell cultures or in a different patient population?
- Is this compounded? Which pharmacy, and is it state-licensed?
- What is the route of administration, and has it been studied?
- What are the known side effects and what is unknown?
- How would we tell whether it is working, objectively?
- What is the exit plan if it is not?
That second-to-last question is the one people skip. If there is no objective way to tell whether a treatment is working, you are relying on how you feel — which is exactly where expectation effects are strongest.
A fair summary
These are not fringe compounds. They have real mechanisms, real research behind them, and in two cases legitimate approved uses. But the distance between the established science and the marketing promise is larger here than for GLP-1 medications, the regulatory ground is moving, and the honest position is uncertainty rather than either dismissal or enthusiasm. Ask the questions above, and expect specific answers.
Ask a licensed clinician
A provider who has reviewed your history can tell you more about whether peptide therapy makes sense for your situation than any article can.
Learn MoreIndependent site. We may earn a commission if you start an assessment through this link. Eligibility is decided by a licensed clinician, not by us.
Not medical advice. General education only. Consult a qualified healthcare professional before starting any medication or therapy.